Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECOLAR: Renal Hemodynamics of Empagliflozin and Losartan in T2DM
NCT04238702Phase 4Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of empagliflozin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Glomerular Filtration Rate at 7 days and Effective Renal Plasma Flow at 7 days. Started Nov 2020; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04238702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04238702.